

Investigate small particles with unparalleled sensitivity
Amnis® CellStream® Flow Cytometry System

For Research Use Only. Not for use in diagnostic procedures.



Luminex®
complexity simplified.



CD137 (ILA/4-1BB), a Member of the TNF Receptor Family, Induces Monocyte Activation via Bidirectional Signaling

This information is current as of October 28, 2021.

Joachim Langstein, Jan Michel, Jana Fritsche, Marina Kreutz, Reinhard Andreesen and Herbert Schwarz

J Immunol 1998; 160:2488-2494; ;
<http://www.jimmunol.org/content/160/5/2488>

References This article **cites 30 articles**, 10 of which you can access for free at:
<http://www.jimmunol.org/content/160/5/2488.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 1998 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



CD137 (ILA/4-1BB), a Member of the TNF Receptor Family, Induces Monocyte Activation via Bidirectional Signaling¹

Joachim Langstein,* Jan Michel,* Jana Fritsche,[†] Marina Kreutz,[†] Reinhard Andreesen,[†] and Herbert Schwarz^{2*}

CD137 (ILA/4-1BB), a member of the TNF receptor family, was shown previously to inhibit proliferation and to induce apoptosis in T lymphocytes. In this study, we identify CD137 as a novel and potent monocyte activation factor. CD137 protein induces expression of IL-6, IL-8, and TNF- α , and inhibits expression of IL-10. Furthermore, CD137 differentially regulates expression of cell surface receptors. It induces expression of ICAM and reduces expression of Fc γ RIII, while levels of HLA-DR remain unchanged. CD137 also promotes adherence of monocytes. These effects of CD137 require immobilization of CD137 protein, indicating that they are mediated by cross-linking of a corresponding ligand/coreceptor expressed on monocytes. *The Journal of Immunology*, 1998, 160: 2488–2494.

The TNF receptor family consists of 13 members characterized by cysteine-rich pseudo-repeats in their extracellular domains. TNFR I and II, TNFR-related protein, p75 nerve growth factor receptor, CD27, CD30, CD40, CD95 (Fas/Apo-1), CD137 (ILA³/4-1BB), OX40, herpesvirus entry mediator (HVEM), APO-2 (DR-4), APO-3 (DR3/WSL-1), and some viral homologues regulate diverse physiologic programs such as proliferation, differentiation, and programmed cell death (1–3). The ligands for these receptors also form a family of structurally related proteins (4).

The human and murine genes induced by lymphocyte activation (ILA) and 4-1BB have been identified in screens for receptors expressed on activated lymphocytes (5–7) and have recently received the nomenclature CD137 (8). CD137 is expressed by activated T and B lymphocytes and monocytes, and expression in primary cells is strictly activation dependent (9). The gene for human CD137 resides on chromosome 1p36, in a cluster of related genes, and this chromosomal region is associated with mutations in several malignancies (10).

Abs to CD137 and cells transfected with the cDNA for the membrane-bound form of the ligand costimulate proliferation of activated T cells (11–13), and CD137 ligand expressed by B lymphocytes costimulates T cell proliferation synergistically with B7 (14). Injected, agonistic anti-CD137 Abs activate T cells sufficiently for rejection of tumors in mice (15).

While agonistic Abs and the ligand to CD137 enhance lymphocyte activation, the CD137 protein has the opposite effect. It inhibits proliferation of activated T lymphocytes and induces programmed cell death. These T cell-inhibitory activities of CD137

require immobilization of the protein, arguing for transmission of a signal through the CD137 ligand (12).

Bidirectional transduction of signals through the receptor as well as the ligand has also been suggested for the OX40, CD40, and CD30 receptor/ligand systems, three other members of the TNF receptor and ligand families (16–19), and the EPH family receptor Nuk and its transmembrane ligands, which are implicated in the regulation of axon guidance, fasciculation, and compartment definition (20).

The murine CD137 ligand is expressed constitutively by stromal cells of the bone marrow and thymus, macrophages, and B cells, and its expression is inducible in T cells (13, 21). Constitutive expression of the human CD137 ligand was reported for monocytes, B cells, and neuroblastoma cells (7). The human and murine CD137 ligands display only 36% homology, compared with 70 to 80% of human-mouse interspecies homology for other TNF family members, implying the existence of yet other, unidentified CD137 ligands.

Monocytes play an essential role in immune surveillance. Dysregulated monocyte activation has been implicated in autoimmune diseases as well as immune deficiencies (22). The process of monocyte activation and especially the regulation of their diverse functions are only partially understood. The ability to modulate monocyte activation and functions would be of eminent therapeutic significance.

In this study, we show that the CD137 ligand system induces monocyte activation, and that this is mediated by signaling through the ligand/coreceptor.

Materials and Methods

Reagents

OKT3 was recovered as a hybridoma supernatant and titrated for optimal T lymphocyte proliferation. LPS (*Salmonella abortus equi*) was kindly provided by C. Galanos (Max-Planck-Institut, Freiburg, Germany). Anti-Fc Ab was purchased from Sigma Chemical Co. (St. Louis, MO), anti-CD16 from CLB (Amsterdam, The Netherlands), and anti-CD54 and anti-HLA-DR from Dianova (Hamburg, Germany).

Cells and cell culture

Human PBMC were prepared by Percoll gradient density centrifugation, as previously described (23). Primary T lymphocytes were isolated by T cell enrichment columns, according to the instructions provided by the manufacturer (R&D Systems, Minneapolis, MN). Primary B lymphocytes were

Departments of *Pathology and [†]Hematology, University of Regensburg, Regensburg, Germany

Received for publication June 26, 1997. Accepted for publication November 17, 1997.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This project was supported by Deutsche Forschungsgemeinschaft.

² Address correspondence and reprint requests to Dr. Herbert Schwarz, Department of Pathology, University of Regensburg, 93042 Regensburg, Germany.

³ Abbreviations used in this paper: ILA, induced by lymphocyte activation; GST, glutathione S-transferase; IL-1Ra, IL-1 receptor antagonist.

isolated by anti-CD20 coupled to magnetic beads (Miltenyi, Bergisch Gladbach, Germany). Primary monocytes were isolated by elutriation, as described previously (24). Elutriated monocytes were more than 95% pure, and contaminating T lymphocytes were less than 3%, as estimated by morphology and antigenic phenotype (CD14, CD3, CD4, CD8 expression). Unless indicated otherwise, cells were cultured in polystyrene dishes (Becton Dickinson, Franklin Lakes, NJ) in RPMI 1640 supplemented with 5% FCS at a concentration of 10^6 /ml. Monocytes cultured in Teflon bags were supplemented with 2% human serum type AB (Pan Systems, Aidenbach, Germany), as described previously (25).

Differential display PCR

Resting PBMC, and PBMC activated with 0.1 and 1 ng/ml anti-CD3 (OKT3) were cultured on plates coated with 10 μ g/ml of the constant domain of Ig (Fc) or a fusion protein, consisting of the extracellular domain of CD137 and Fc (CD137-Fc). Aliquots of PBMC were harvested after 6 and 18 h. Poly(A)⁺ RNA was isolated from 5×10^6 PBMC using RNazol B (Tel-Test, Friendswood, TX) and the Poly(A)Tract system (Promega Corp., Madison, WI). First-strand cDNA synthesis was performed with 3% of isolated mRNA in a 40- μ l reaction. Two-nucleotide-anchored oligo(dT) primers (1 μ M), 400 U SuperScriptII RNaseH-RT (Life Technologies, Eggenstein, Germany), and 25 μ M dNTP were used.

Five percent of the reverse transcriptase reaction served as template for PCR with decameric primers. PCR was performed in 20 μ l vol with 1 U *Taq* DNA polymerase (Boehringer Mannheim Corp., Mannheim, Germany), 200 μ M dNTPs, 1.5 mM MgCl₂, 10 mM Tris, pH 8.3, 50 mM KCl, and 10 μ M of each primer. After a 5-min denaturation step at 94°C, the reaction proceeded in 40 cycles of 1 min at 94°C, 1 min at 40°C, and 10 s at 72°C, followed by 10 min at 72°C. Reaction products were separated on nondenaturing polyacrylamide gels.

One-third of the PCR reaction was loaded on a nondenaturing 10% polyacrylamide gel, and electrophoresis was performed at 200 V for 10 min, followed by 500 V for 1 h. For detection of DNA fragments, the gel was silver stained. Differentially regulated PCR products were excised from the gel and isolated by shaking for 2 h in 50 μ l 10 mM Tris, pH 8, at 65°C. Fragments were reamplified by 40 cycles of PCR using identical primers as in the first PCR, purified by PCR purification kit (Qiagen, Hilden, Germany), cloned into pT7Blue(R) (Novagen, Madison, WI), and sequenced.

ELISA

ELISA kits were purchased from R&D Systems (Wiesbaden, Germany) and performed according to the manufacturer's instructions. Cytokine concentrations in triplicate supernatants are expressed as mean \pm SEM.

Immunofluorescence staining and flow-cytometry analysis

Cells were analyzed using a FACScan (Becton Dickinson, Mountain View, CA). A quantity amounting to 5×10^5 cells per condition was washed twice in cold PBS, containing 0.06% Ig (Sandoz Pharma AG, Basel, Switzerland), incubated with primary, Ag-specific Abs or isotype-matched control Abs, washed, and incubated with saturating concentrations of FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) for 30 min at 4°C. Cells were washed an additional two times and fixed with 1% paraformaldehyde in PBS.

Results

Identification of IL-8 as a CD137-regulated gene by differential display

To identify genes that are regulated by CD137, we performed differential display PCR. Only PCR fragments that appeared to be regulated differentially by CD137 in resting and in activated PBMC, at 6 and 18 h of culture, and whose intensities were modulated by CD137 at least by a factor of 5, were included in further analysis. Two fragments that were obtained by independent PCR reactions, using different pairs of primers, turned out to be fragments of the IL-8 cDNA. According to the results from the differential display PCR, CD137 induced IL-8 mRNA expression (not shown).

We confirmed induction of IL-8 mRNA expression by CD137 by Northern blot analysis (Fig. 1A). IL-8 mRNA was induced 10-fold by CD137, as determined by densitometry of the autoradiograph. IL-8 protein in supernatants of CD137-treated and control




FIGURE 1. Induction of IL-8 by CD137. *A*, Resting PBMC (5×10^7 /condition) were plated on tissue culture plates coated with 10 μ g/ml Fc or CD137-Fc protein. Total RNA was isolated after 8 h and analyzed by Northern blot analysis. Hybridization was performed with the IL-8 cDNA fragment isolated by differential display PCR. Equal load of RNA (20 μ g/lane) was controlled by a rehybridization with β -actin cDNA. *B*, Supernatants of cultures from *A* were harvested after 8 h, and concentrations of IL-8 were determined by ELISA. Identical results were obtained with cells from eight different donors in five independent experiments.

PBMC was measured by ELISA. We found a 10-fold induction of IL-8 protein by CD137 in supernatants of PBMC, matching the degree of induction of IL-8 mRNA (Fig. 1B).

Cytokine profile induced by CD137

Investigating purified subpopulations of PBMC, we found that IL-8 was produced mainly by monocytes, to a lesser extent by B lymphocytes, but not by total lymphocytes and purified T lymphocytes (Fig. 2A). Furthermore, IL-8 could not be induced by CD137 in the T and B cell lines Jurkat, Molt4, and Raji, respectively (not shown).

The level of cytokine induction was a direct function of the concentration of CD137 protein (Fig. 2B). Coating with as low as 100 ng/ml of CD137 protein did result in a significant induction of IL-8 in monocytes.

Having demonstrated induction of IL-8 in monocytes by CD137, we reasoned that other cytokines may be regulated by CD137 as well. We found induction of IL-6 and TNF- α by CD137 in monocytes (Fig. 3A). No IL-12 was induced by CD137 (not shown).




FIGURE 2. IL-8 is induced in monocytes, but not in lymphocytes. *A*, 10^5 primary T and B lymphocytes and monocytes were plated in $100 \mu\text{l}$ on tissue culture dishes coated with $10 \mu\text{g/ml}$ Fc and CD137-Fc, respectively. Supernatants were harvested after 16 h, and concentrations of IL-8 were determined by ELISA. Comparable results were obtained with cells from three different donors in two independent experiments. *B*, Dose-response curve of IL-8 induction by CD137. A quantity amounting to 10^5 primary monocytes in $100 \mu\text{l}$ was plated on tissue culture dishes coated with indicated concentrations of Fc or CD137-Fc protein. The concentration of IL-8 was determined after 16 h.

CD137 exerted its effects on cytokine release within the first 16 h of culture, and levels of IL-8 remained at its maximum for 5 days (Fig. 3*B*). LPS is a key activator of monocytes. To assess the potency of CD137 as a monocyte activator, we compared the efficiencies of the two molecules in inducing cytokine release from monocytes. Maximal induction of IL-8 by LPS was already achieved at a concentration of 10 ng/ml (not shown) and was about twofold higher than the IL-8 level induced by CD137 (Fig. 3*B*). A potential interaction of the two molecules was examined by exposing monocytes to the combination of LPS and CD137. CD137 further enhanced the maximal levels of IL-8 induced by LPS.

CD137 did not induce expression of IL-10, rather it reduced the expression of IL-10 in activated monocytes. CD137 and LPS did induce expression of IL-1Ra, and a slight decrease in IL-1Ra levels was obtained with the combination of CD137 and LPS (Fig. 3*C*).

Verification of CD137 activities

We wanted to verify that the observed effects of CD137 on monocytes were genuine and not due to some nonspecific activation or endotoxin contamination associated with the CD137 protein preparation. Plates were coated with an anti-CD137 Ab (M127) or an isotype-matched control Ab (mouse IgG). After blocking of nonspecific binding sites, Fc and CD137-Fc proteins were added, plates were washed, and PBMC were cultured in these wells for 16 h. In this study, IL-6 as a readout cytokine was only produced by cultures in which CD137-Fc protein was presented by the anti-CD137 Ab (Fig. 4*A*). In addition, blocking of the protein-binding capacity of the tissue culture plates before addition of PBMC and CD137-Fc protein to the cultures completely inhibited induction of IL-6 (Fig. 4*B*). The presence of soluble CD137 did not induce IL-6.

As a second control experiment, we tested effects of CD137 protein isolated from a different source. CD137 produced by the baculovirus expression system as a fusion protein with glutathione *S*-transferase (GST) (26) induced expression of IL-8 as efficiently as did the CD137-Fc protein (Fig. 4*B*).

CD137 regulates expression of cell surface receptors in monocytes

Another fragment identified in the differential screen as being down-regulated by CD137 was $\text{Fc}\gamma\text{RIII}$ (CD16). Using Northern blot analysis, we confirmed a reduction of $\text{Fc}\gamma\text{RIII}$ expression by about one-half in monocytes in response to CD137 (Fig. 5*A*). Expression of CD54 (ICAM) was enhanced by about 50% by CD137 (mean = 135 vs 90), while levels of HLA-DR expression remained unchanged (mean = 108 vs 113) (Fig. 5*B*).

CD137 promotes adherence of monocytes

In the PBMC cultures used for differential display, we noticed that CD137 greatly enhanced adherence of cells, which had the appearance of monocytes, to the tissue culture dishes (not shown). We confirmed the adherence-promoting effect of CD137 on primary monocytes by plating monocytes on dishes to which they adhere only weakly. Monocytes plated on CD137-Fc-coated dishes displayed a profoundly enhanced attachment within 2 h of plating of the cells. Significantly fewer cells attached when monocytes were plated on Fc-coated or uncoated dishes. In addition, dishes coated with an Ab to HLA-DR did not lead to an enhanced attachment of monocytes (not shown).

Immobilization of CD137 is required for activation of monocytes

Adherence of monocytes was enhanced by immobilized CD137, but not by soluble CD137 (not shown). This result is consistent with induction of IL-6 by immobilized, but not by soluble CD137 (Fig. 4*B*). Alternatively to immobilization of CD137 protein on tissue culture plates, soluble CD137-Fc protein could be used for induction of cytokines when it was cross-linked via anti-Fc Abs (Fig. 6).

Discussion

In a differential screen for genes of which the expression in PBMC is regulated by the TNF receptor family member CD137, we identified IL-8 and $\text{Fc}\gamma\text{RIII}$, two genes expressed by monocytes. In addition, we noticed that monocytes attached in by far greater numbers to culture dishes that were precoated with CD137 protein. These observations led us to an investigation of the influence of CD137 on monocyte functions.

CD137 induced expression and release of cytokines by monocytes. Concentrations of cytokines induced by CD137 were in the







FIGURE 3. Regulation of cytokine synthesis by CD137. *A*, 10^5 primary monocytes in $100 \mu\text{l}$ were plated on tissue culture dishes coated with $10 \mu\text{g/ml}$ Fc or CD137-Fc protein. Supernatants were harvested after 16 h, and concentration of IL-6, IL-8, and TNF- α was determined by ELISA. *B*, Time course of IL-8 induction by CD137. A quantity amounting to 10^5 primary monocytes in $100 \mu\text{l}$ was plated on tissue culture dishes coated with $5 \mu\text{g/ml}$ Fc or CD137-Fc protein, with and without the addition of LPS (10 ng/ml). IL-8 concentrations were determined at indicated times. *C*, Monocytes were exposed to LPS (50 ng/ml) or immobilized CD137-Fc ($10 \mu\text{g/ml}$), or both. Supernatants were harvested after 16 h, and concentrations of IL-10 (*left panel*) and IL-1Ra (*right panel*) were determined by ELISA. There was no difference between LPS alone and Fc + LPS (not shown). The experiments were performed twice with cells from independent donors and similar results.

FIGURE 4. Verification of IL-8 induction by CD137. **A**, Tissue culture plates were coated with mouse IgG (mIgG) and the anti-CD137 Ab M127 (10 $\mu\text{g/ml}$) at 4°C overnight. Unspecific binding was blocked by 3% dry milk in PBS for 1 h at room temperature. Fc and CD137-Fc proteins (10 $\mu\text{g/ml}$) were added for 1 h at room temperature, and unbound protein was removed by washing with PBS and 0.05% Triton X-100. PBMC (10^5) were plated in each well, and IL-6 concentrations in 16-h supernatants were determined by ELISA. **B**, Tissue culture plates were left untreated (immobilized), or incubated with FCS for saturation of their protein-binding capacity (soluble), before PBMC (10^5 /well) and Fc or CD137-Fc proteins (10 $\mu\text{g/ml}$) were added. IL-6 concentrations in 16-h supernatants were determined by ELISA. **C**, 10^5 resting PBMC were plated on tissue culture plates coated with 10 $\mu\text{g/ml}$ GST and GST-CD137, respectively. Concentrations of IL-8 were determined by ELISA in 16-h supernatants.



same range as the ones found in gouty synovial fluid, emphysema fluid, and parapneumonic effusions (27, 28). Compared with LPS, CD137 proved to be a weaker stimulator of monocyte activation. As LPS is one of the most potent activators of monocytes, this result was not surprising. But interestingly, CD137 was able to further enhance the maximal levels of IL-8 elicited by LPS, indicating independent mechanisms of monocyte activation by the two molecules.

In line with the induction of cytokines such as IL-6, IL-8, and TNF- α , which in general enhance immune responses, is the inhibition of IL-10, which is associated with a deactivation of monocytes (29). Therefore, one may conclude that CD137 participates in the regulation of the inflammatory cascade. The opposite effects of CD137 and LPS on IL-10 production also argue for separate monocyte activation mechanisms of the two molecules.

IL-12 is a cytokine known for thriving and characterizing a Th1-type immune response. The circumstance that CD137 did not induce IL-12 suggests that CD137 may favor a Th2-, rather than a Th1-type immune response.

CD137 induced cytokines mainly in monocytes. No induction or only weak induction of cytokines by CD137 was found for T and B lymphocytes, respectively. Activation of monocytes by CD137 was observed with cells from several donors and was obtained with PBMC, as well as with purified monocytes. However, about

fivefold higher levels of cytokines were induced in PBMC compared with purified monocytes, indicating an enhancement of the CD137 effect by lymphocytes or other blood cells.

CD137 also regulated expression of cell surface receptors on monocytes. The specificity of this regulation is evidenced by the selective and partially opposite regulation of different markers. The induction of ICAM, a monocyte activation marker, is consistent with the induction of cytokines that are produced by activated monocytes. Up-regulation of Fc γ RIII and MHC class II are features of monocytes differentiating to macrophages (30). CD137 had no effect on MHC class II expression and reduced Fc γ RIII, results in line with the concept of CD137 delivering rather an activation than a differentiation signal.

Concomitantly with alterations in gene expression, CD137 enhanced the attachment of monocytes to tissue culture dishes. Since monocytes readily attach to many surfaces, the adherence-promoting activity of CD137 was best visible when tissue culture dishes were used, which on their own support monocyte attachment only poorly. This effect of CD137 on monocytes occurred fast and was already clearly visible 2 h after plating of the cells. Monocyte attachment mediated by CD137 is not due to a passive capturing of the cells, as evidenced by the accompanying morphologic changes, and also because anti-HLA-DR Abs had no influence on monocyte adherence.




FIGURE 5. Regulation of surface receptor expression by CD137. *A*, 5×10^7 primary monocytes were plated on tissue culture dishes coated with $10 \mu\text{g/ml}$ Fc or CD137-Fc protein. RNA was isolated after 16 h and analyzed by Northern blot analysis. Hybridization was performed with the FcγRIII cDNA fragment isolated by differential display PCR. Equal load of RNA ($20 \mu\text{g/lane}$) was controlled by a rehybridization with β-actin cDNA. *B*, Monocytes were cultured in Teflon bags at a concentration of 10^6 cells/ml. Fc or CD137-Fc protein ($2 \mu\text{g/ml}$) was added and cross-linked by anti-Fc Ab ($4 \mu\text{g/ml}$). Monocytes were stained for expression of




FIGURE 6. Immobilization of CD137 is required for monocyte activation. Monocytes were cultured in Teflon bags at a concentration of 10^6 cells/ml. Fc and CD137-Fc proteins ($2 \mu\text{g/ml}$) were added and cross-linked by anti-Fc Ab ($4 \mu\text{g/ml}$). Concentrations of IL-8 were determined after 16 h. Identical results were obtained with monocytes from two different donors in two independent experiments.

Induction of cytokine synthesis by adherence is a well-known phenomenon in monocytes (31, 32). In the case of CD137, induction of cytokine and ICAM expression is not a mere consequence of the CD137-mediated increase in the adherence of monocytes. In monocytes that were cultured under nonadherent conditions, cross-linked CD137 also induced expression of ICAM and IL-8.

The sum of our data, the induction of cytokines, the induction of activation markers, the enhancement of adherence, and the reduction of expression of differentiation markers all argue for CD137 being a basic mediator of monocyte activation.

To rule out that activation of monocytes by CD137 was due to some trivial cause such as a contamination of the CD137 protein preparation with endotoxin, we performed several control experiments. We demonstrated that 1) CD137 protein isolated from a different source induces cytokine synthesis as well; 2) CD137 protein, specifically captured and presented by anti-CD137 Abs, and after washing out any potential contaminants, still induced cytokine synthesis; and 3) administering CD137 protein in soluble form by preventing its immobilization did not induce cytokines. In addition, CD137 counteracted LPS-induced IL-10 synthesis.

Engagement of FcR on monocytes can trigger cytokine release (33). Therefore, Fc protein served as a negative control in all of our experiments in which CD137-Fc fusion protein was used. Still, the possibility could not be excluded that the effects of CD137-Fc observed were due to a combined action of FcR and CD137 ligand engagement. However, the fact that a fusion protein consisting of GST and the extracellular domain of CD137 induced IL-8 as efficiently as the CD137-Fc fusion protein suggests that the activation of monocytes can be mediated solely by CD137.

ICAM (*upper panel*) and HLA-DR (*lower panel*) after 16 h. Identical results were obtained with monocytes from two different donors in two independent experiments.

T lymphocytes receive an activation signal from CD137 cross-linking, leading to enhanced proliferation and an effective antitumor response (11–15). Monocytes do express CD137 ligand (7, 20) and are activated by cross-linking of the CD137 ligand. Therefore, a scenario is conceivable in which T lymphocytes and monocytes mutually activate each other via interaction of CD137 on lymphocytes with its ligand on monocytes, leading to an enhancement and perpetuation of an immune response. Supported by this view is the finding that CD137 induces a stronger cytokine expression in PBMC, as in purified monocytes.

Activation of monocytes stands in contrast with the inhibition of proliferation and the induction of programmed cell death in T lymphocytes by CD137 protein (12). The clarification of the physiologic significance of these opposite effects of CD137 protein on T lymphocytes and monocytes will be an important topic of future experiments.

Inhibition of proliferation and induction of apoptosis in T lymphocytes by CD137 protein require immobilization of the protein (12). Immobilization of CD137 protein was also necessary for activation of monocytes. Immobilization of CD137 could be achieved via coating of the protein to tissue culture dishes, or by addition of soluble CD137-Fc and cross-linking via anti-Fc Abs. This requirement for immobilization of CD137 protein implies transmission of a signal through a CD137 ligand, which is expressed on monocytes and T lymphocytes and is cross-linked by immobilized CD137 protein.

The ligands for CD30, OX40, and CD40, other members of the TNF superfamily, have also been implicated in delivering signals to the cells they are expressed on (16–19). Since in the TNF superfamily ligands occur not only as soluble, but also as membrane-bound proteins, a bidirectional transduction of signals through the receptor as well as the respective ligand is possible. Bidirectional transmission of a signal through receptor and ligand recently has been documented for an EPH receptor and its membrane-bound ligands (20). This mechanism probably allows a more precise fine tuning of immune responses by delivering a direct and immediate feedback signal to the ligand-bearing cell.

Our data on CD137-mediated monocyte activation imply that it should be worthwhile to test whether inhibition of the interaction of CD137 with its ligand can inhibit or reduce monocyte activation and possibly ameliorate acute and chronic inflammatory diseases.

Acknowledgments

We thank Gitte Krause and Ute Ackermann for excellent technical assistance, and Drs. M. Widmer and R. G. Goodwin (Immunex Corp., Seattle, WA) for CD137-Fc protein.

References

1. Beutler, B., and C. van Huffel. 1994. Unraveling function in the TNF ligand and receptor families. *Science* 264:667.
2. Smith, C. A., T. Farrah, and R. G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. *Cell* 76:959.
3. Lotz, M., M. Setareh, J. von Kempis, and H. Schwarz. 1996. The nerve growth factor/tumor necrosis factor receptor family. *J. Leukocyte Biol.* 60:1.
4. Gruss, H. J., and S. K. Dower. 1995. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. *Blood* 85:3378.
5. Kwon, B. S., and S. M. Weissman. 1989. cDNA sequences of two inducible T-cell genes. *Proc. Natl. Acad. Sci. USA* 86:1963.
6. Schwarz, H., J. Tuckwell, and M. Lotz. 1993. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve growth factor/tumor necrosis factor receptor family. *Gene* 134:295.
7. Alderson, M. R., C. A. Smith, T. W. Tough, T. Davis-Smith, R. J. Armitage, B. Falk, E. Roux, E. Baker, G. R. Sutherland, W. S. Din, and R. G. Goodwin. 1994. Molecular and biological characterization of human 4-1BB and its ligand. *Eur. J. Immunol.* 24:2219.
8. Kishimoto, T., S. Goyert, H. Kikutani, D. Manson, M. Miyasaka, L. Moretta, T. Ohno, K. Okumura, S. Shaw, T. A. Spriner, K. Sagamura, H. Sugawara, A. E. Kr. von dem Borne, and H. Zola. 1997. Update of CD antigens, 1996. *J. Immunol.* 158:3035.

9. Schwarz, H., J. Valbracht, J. Tuckwell, J. Kempis, and M. Lotz. 1995. ILA, the human 4-1BB homologue is inducible in lymphoid and other cell lines. *Blood* 85:1043.
10. Schwarz, H., K. Arden, and M. Lotz. 1997. CD137, a member of the tumor necrosis factor receptor family is located on chromosome 1p36, in a cluster of related genes, and colocalizes with several malignancies. *Biochem. Biophys. Res. Commun.* 235:699.
11. Pollok, K. E., Y. J. Kim, Z. Zhou, J. Hurtado, K. K. Kim, R. T. Pickard, and B. S. Kwon. 1993. Inducible T cell antigen 4-1BB: analysis of expression and function. *J. Immunol.* 150:771.
12. Schwarz, H., F. Blanco, J. Valbracht, J. Kempis, and M. Lotz. 1996. ILA, a member of the human NGF/TNF receptor family regulates T lymphocyte proliferation and survival. *Blood* 87:2839.
13. Goodwin, R. G., W. S. Din, T. Davis-Smith, D. M. Anderson, S. D. Gimpel, T. A. Sato, C. R. Maliszewski, C. I. Brannan, N. G. Copeland, N. A. Jenkins, T. Farrah, R. J. Armitage, W. C. Fanslow, and C. A. Smith. 1993. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. *Eur. J. Immunol.* 10:2631.
14. DeBenedette, M. A., N. R. Chu, K. E. Pollok, J. Hurtado, W. F. Wade, B. S. Kwon, and T. H. Watts. 1995. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its up-regulation on M12 B lymphomas by cAMP. *J. Exp. Med.* 181:985.
15. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellström, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against 4-1BB T cell activation molecule eradicate established tumors. *Nat. Med.* 3:682.
16. Stuber, E., M. Neurath, D. Calderhead, H. P. Fell, and W. Strober. 1995. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. *Immunity* 2:507.
17. Grewal, I. S., J. Xu, and R. A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. *Nature* 378:617.
18. Van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced costimulation of T cells in the development of helper function. *Nature* 378:620.
19. Wiley, R. W., R. G. Goodwin, and C. A. Smith. 1996. Reverse signaling via CD30 ligand. *J. Immunol.* 157:3635.
20. Holland, S. J., N. W. Gale, G. Mbamalu, G. D. Yancopoulos, M. Henkemeyer, and T. Pawson. 1996. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. *Nature* 383:722.
21. Pollok, K. E., Y. J. Kim, J. Hurtado, Z. Zhou, K. K. Kim, and B. S. Kwon. 1994. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. *Eur. J. Immunol.* 24:367.
22. Lewis, C. E., and J. O'D. McGee. 1992. The Macrophage. IRL Press at Oxford University Press, Oxford.
23. Langstein, J., F. Hofstaedter, and H. Schwarz. 1996. *cis*-9,10-Octadecenoamide, a sleep-inducing brain lipid, inhibits lymphocyte proliferation. *Res. Immunol.* 147:389.
24. Andreesen, R., W. Brugger, C. Scheibenbogen, M. Kreutz, H. G. Leser, A. Rehm, and G. W. Lohr. 1990. Surface phenotype analysis of human monocyte to macrophage maturation. *J. Leukocyte Biol.* 47:490.
25. Andreesen, R., J. Picht, and G. W. Lohr. 1983. Primary cultures of human blood-borne macrophages grown on hydrophobic Teflon membranes. *J. Immunol. Methods* 56:295.
26. Langstein, J., C. Buechler, and H. Schwarz. 1996. Recovery of functional, recombinant baculovirus produced proteins from insect cell inclusion bodies. In *Technical Tips Online* (<http://www.elsevier.com/locate/tto>). Identifier No. T40070.
27. Terkeltaub, R., C. Zachariae, D. Santoro, J. Martin, P. Peveri, and K. Matsushima. 1991. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. *Arthritis Rheum.* 34:894.
28. Antony, V. B., S. W. Godbey, S. L. Kunkel, J. W. Hott, D. L. Hartman, M. D. Burdick, and R. M. Strieter. 1994. Recruitment of inflammatory cells to the pleural space: chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. *J. Immunol.* 151:7216.
29. Geng, Y., E. Gulbins, A. Altman, and M. Lotz. 1994. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. *Proc. Natl. Acad. Sci. USA* 91:8602.
30. Koch, A. E., J. C. Burrows, A. Skoutelis, R. Marder, P. H. Domer, B. Anderson, and S. J. Leibovich. 1991. Monoclonal antibodies detect monocyte/macrophage activation and differentiation antigens and identify functionally distinct subpopulations of human rheumatoid synovial tissue macrophages. *Am. J. Pathol.* 138:65.
31. Beekhuizen, H., and R. van-Furth. 1993. Monocyte adherence to human vascular endothelium. *J. Leukocyte Biol.* 54:363.
32. Heinel, L. A., D. Singleton, M. Miller, M. B. Frewin, and P. W. Gudewicz. 1995. Monocyte adherence to the subendothelial basement membrane increases interleukin-8 gene expression and antigen release. *Inflammation* 19:517.
33. Krutmann, J., R. Kirnbauer, A. Kock, T. Schwarz, E. Schopf, L. May, P. Selgal, and T. Luger. 1990. Cross-linking Fc receptors on monocytes triggers IL-6 production: role in anti-CD3-induced T cell activation. *J. Immunol.* 145:1337. Monocytes were cultured in Teflon bags at a concentration of 10^6 cells/ml. Fc and CD137-Fc proteins (2 μ g/ml) were added and cross-linked by anti-Fc Ab (4 μ g/ml). Concentrations of IL-8 were determined after 16 h. Identical results were obtained with monocytes from two different donors in two independent experiments.